36616-28-1

Basic information

• Product Name: N-[4-(2-chloroethoxy)phenyl]acetamide
• Synonyms: N-(4-(2-Chloroethoxy)phenyl)acetamide
• CAS NO: 36616-28-1
• Molecular Formula: C₁₀H₁₂ClNO₂
• Molecular Weight: 213.6608
• EINECS: 253-127-0
• Mol File: 36616-28-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 403.8°C at 760 mmHg
• Flash Point: 198°C
• Density: 1.225g/cm³
• Vapor Pressure: 9.88E-07mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: N-[4-(2-chloroethoxy)phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(2-chloroethoxy)phenyl]acetamide(36616-28-1)
• EPA Substance Registry System: N-[4-(2-chloroethoxy)phenyl]acetamide(36616-28-1)

Safety Data

• Hazardous Substances Data: 36616-28-1(Hazardous Substances Data)

Upstream product

• 80-41-1 2-chloroethyl tosylate 
• 103-90-2 4-acetaminophenol 
• 3383-72-0 1-(2-chloroethoxy)-4-nitrobenzene 
• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 
• 100-02-7 4-nitro-phenol 
• 107-04-0 1-Bromo-2-chloroethane 
• 50375-15-0 2-[4-(acetylamino)phenoxy]ethanol 
• 16670-48-7 2-chloroethyl benzenesulfonate 

Downstream Products

• 59954-07-3 acetic acid-[4-(2-piperidino-ethoxy)-anilide] 
• 102667-15-2 1-[2-(4-acetylamino-phenoxy)-ethyl]-4-phenyl-piperidine-4-carboxylic acid ethyl ester 
• 28276-96-2 acetic acid-[4-(2-diethylamino-ethoxy)-anilide] 
• 672961-06-7 N-[4-(2-chloroethoxy)-2-nitrophenyl]acetamide 
• 38948-27-5 4-(2-(piperidin-1-yl)ethoxy)aniline 
• 856400-15-2 2-nitro-4-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethoxy)aniline 
• 1027427-91-3 4-[2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)-ethoxy]-benzene-1,2-diamine 

Relevant articles and documents

Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs

5-[3-(4-Arylpiperazin-1-yl)propyl]-1H-benzimidazoles and 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazoles were synthesized and their affinity for the D1, D2 and 5-HT1A receptors examined. They expressed a rather high affinity for the D2 dopamine receptor. The main features of ligand-D2 receptor interactions revealed by docking analyses were: salt bridge between piperazine ring protonated N1 and Asp 86, hydrogen bonds of ligand bezimidazole part with Ser 141, Ser 122 and His 189, edge-to-face interactions of arylpiperazine aromatic ring with Phe 178, Tyr 216 and Trp 182 and hydrogen bond between ethereal oxygen in ethylenoxy ligands and hydrogen of Phe 185 or Trp 115. The most active 5-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]ethoxy}-1,3-dihydro-2H- benzimidazole-2-thione (27) has a maximal number of attractive interactions. A satisfactory correlation between docking of the compounds into the D2 receptor and competition binding results was observed.

NOVEL COMPOUNDS HAVING A DOPAMINERGIC AND/OR SEROTONINERGIC ACTIVITY

The invention relates to novel compounds of 4-[2-(4-arylpiperazin-1-yl)-ethoxy]benzo-1,2-diamine I, to the derivatives thereof in the form of benzoimidazole-2-thiones, benzoimidazoles and benzotriazoles, to the use of the pharmacologically acceptable salts thereof as dopaminergic and serotoninergic agents, and to a method for producing said compounds.

2- OR 3-(SUBSTITUTEDAMINOALKOXYPHENYL)QUINAZOLIN-4-ONES

This invention relates to 2-or 3-(substituted aminoalkoxyphenyl) quinazolin-4-ones which are partial estrogen agonists and are useful in treating osteoporosis, prostatic hypertrophy, breast cancer and endometrial cancer.